Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
18.05
+0.12 (0.67%)
Nov 21, 2024, 4:00 PM EST - Market closed
Entrada Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Nov '24 Nov 21, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Market Capitalization | 639 | 503 | 424 | 534 | - | - |
| Market Cap Growth | 7.07% | 18.72% | -20.71% | - | - | - |
| Enterprise Value | 251 | 219 | 236 | 610 | - | - |
| Last Close Price | 18.05 | 15.09 | 13.52 | 17.12 | - | - |
| PS Ratio | 2.97 | 3.90 | - | - | - | - |
| PB Ratio | 1.51 | 2.08 | 1.99 | 1.79 | - | - |
| P/TBV Ratio | 1.33 | 2.08 | 1.99 | 1.79 | - | - |
| P/FCF Ratio | - | 3.75 | - | - | - | - |
| P/OCF Ratio | - | 3.60 | - | - | - | - |
| EV/Sales Ratio | 1.17 | 1.69 | - | - | - | - |
| EV/FCF Ratio | - | 1.63 | - | - | - | - |
| Debt / Equity Ratio | 0.15 | 0.28 | 0.12 | - | - | - |
| Debt / EBITDA Ratio | 0.81 | 4.68 | - | - | - | - |
| Debt / FCF Ratio | - | 0.51 | - | - | - | - |
| Asset Turnover | 0.41 | 0.36 | - | - | - | - |
| Quick Ratio | 6.42 | 2.26 | 8.62 | 43.32 | 11.62 | 8.77 |
| Current Ratio | 6.59 | 2.33 | 9.55 | 44.46 | 11.89 | 9.08 |
| Return on Equity (ROE) | 16.43% | -2.94% | -37.01% | -30.19% | -93.94% | - |
| Return on Assets (ROA) | 6.95% | -0.55% | -21.79% | -18.29% | -53.97% | - |
| Return on Capital (ROIC) | 9.03% | -0.72% | -22.63% | -18.86% | -59.03% | - |
| Earnings Yield | 8.60% | -1.33% | -22.33% | -9.57% | - | - |
| FCF Yield | -2.73% | 26.68% | -22.82% | -10.38% | - | - |
| Buyback Yield / Dilution | -9.14% | -5.61% | -399.27% | -467.09% | -18.45% | - |
| Total Shareholder Return | -9.14% | -5.61% | -399.27% | -467.09% | -18.45% | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.